Clinical Trials on Locally Advanced Bladder Carcinoma

Total 2892 results

The Netherlands Cancer Institute

Completed

Olaparib and Radiotherapy in Inoperable Breast Cancer

Locally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast Carcinoma

Netherlands
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma

United States
Spanish Breast Cancer Research Group
Seagen Inc.

Recruiting

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)

HER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast Carcinoma

Spain
Seoul National University Hospital
Seoul National University Bundang Hospital; SMG-SNU Boramae Medical Center

Active, not recruiting

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Locally Advanced or Metastatic NSCLC

Korea, Republic of
M.D. Anderson Cancer Center

Terminated

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Novartis Pharmaceuticals

Completed

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Metastatic or Locally Advanced Solid Tumors

Netherlands, Spain, Germany, Switzerland, Belgium
AstraZeneca

Completed

Asia PDL1 Study Among NSCLC Patients (MEDI-APEX)

Locally Advanced or Metastatic NSCLC

Korea, Republic of, China, Japan
University Health Network, Toronto
Canadian Association of Radiation Oncology

Completed

Healthy Bones Study

Locally Advanced Malignant Neoplasm

Canada
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Locally Advanced or Metastatic NSCLC

China
Incyte Corporation

Active, not recruiting

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors

France, Spain, United States, China, United Kingdom, Lithuania, Germany, Ukraine, Finland, Italy, Belgium, Australia, Bulgaria, Latvia, New Zealand, Poland
Amgen

Terminated

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas | Locally Advanced | Unresectable

Spain, Belgium, Denmark, Poland, United States, Korea, Republic of, Russian Federation, Austria, Portugal, United Kingdom, Germany, Hungary, Czech Republic
Hospital Universitario Doctor Peset

Recruiting

Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer (RADI-S)

Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

Stage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma

United States
Xuekui Liu

Not yet recruiting

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma (CZCNRHNSCC)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Neoadjuvant Therapy | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Tango Therapeutics, Inc.

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor

United States, Spain, France
Hospital Universitario de Fuenlabrada

Recruiting

En Bloc TURBT With Collins Loop vs Conventional TURBT (TURBT)

Bladder Cancer | Urothelial Carcinoma Recurrent | Bladder Urothelial Carcinoma | Bladder Neoplasm | Bladder Cancer Stage

Spain
Krzysztof Misiukiewicz
Regeneron Pharmaceuticals

Recruiting

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States
Guiyang Medical University

Unknown

Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Mt. Sinai Medical Center, Miami
Amgen

Completed

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Unresectable Locally Advanced NSCLC

United States
IRCCS San Raffaele

Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditions

Italy
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors

Transitional Cell Carcinoma | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma
Nykode Therapeutics ASA
Nektar Therapeutics; Vaccibody AS

Completed

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer (DIRECT-01)

Locally Advanced or Metastatic Solid Tumours

Germany
Tango Therapeutics, Inc.

Recruiting

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor

United States, France
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
Sesen Bio, Inc.

Completed

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Urinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors

United States, Canada
Beijing Friendship Hospital
Changhai Hospital; The First Affiliated Hospital of Anhui Medical University; Fudan University and other collaborators

Recruiting

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Locally Advanced Rectal Carcinoma

China
University of Hull
Hull University Teaching Hospitals NHS Trust

Not yet recruiting

Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Sixth Affiliated Hospital, Sun Yat-sen University

Active, not recruiting

Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma
Sixth Affiliated Hospital, Sun Yat-sen University

Completed

Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Recurrent Head and Neck Carcinoma | Locally Advanced Head and Neck Carcinoma

United States
Nelson Yee
Ipsen

Active, not recruiting

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Locally Advanced Pancreatic Carcinoma(LAPC)

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Rain Oncology Inc

Withdrawn

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Melanoma | Renal Cell Carcinoma | Gastric Cancer | NSCLC | Mesothelioma | Advanced Solid Tumor | Pancreas Adenocarcinoma | Urothelial Carcinoma Bladder | HNSCC | CDKN2A
Palobiofarma SL
Ohio State University

Active, not recruiting

PBF-1129 in Patients With NSCLC

Locally Advanced or Metastatic NSCLC

United States
Seoul National University Hospital
AstraZeneca; Korean Cancer Study Group

Completed

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Locally Advanced or Metastatic NSCLC

Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Superficial Bladder Urothelial Carcinoma

United States
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
University of Hull
Hull University Teaching Hospitals NHS Trust

Not yet recruiting

Exercise for Improving Radiotherapy Efficacy in Rectal Cancer

Locally Advanced Rectal Carcinoma
Tehran University of Medical Sciences

Not yet recruiting

Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer (TEHRAN)

Locally Advanced Rectal Carcinoma
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
National Cancer Institute, Egypt

Completed

Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma

Egypt
Sichuan Provincial People's Hospital
Xijing Hospital

Unknown

Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy (President)

Locally Advanced Gastric Carcinoma

China

Clinical Trials on Locally Advanced Bladder Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations